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ABSTRACT
Background Rectal cancers show a highly varied 
response to neoadjuvant radiotherapy/chemoradiation 
(RT/CRT) and the impact of the tumor immune 
microenvironment on this response is poorly understood. 
Current clinical tumor regression grading systems 
attempt to measure radiotherapy response but are 
subject to interobserver variation. An unbiased and unique 
histopathological quantification method (change in tumor 
cell density (ΔTCD)) may improve classification of RT/
CRT response. Furthermore, immune gene expression 
profiling (GEP) may identify differences in expression levels 
of genes relevant to different radiotherapy responses: (1) 
at baseline between poor and good responders, and (2) 
longitudinally from preradiotherapy to postradiotherapy 
samples. Overall, this may inform novel therapeutic RT/
CRT combination strategies in rectal cancer.
Methods We generated GEPs for 53 patients from 
biopsies taken prior to preoperative radiotherapy. TCD 
was used to assess rectal tumor response to neoadjuvant 
RT/CRT and ΔTCD was subjected to k- means clustering 
to classify patients into different response categories. 
Differential gene expression analysis was performed 
using statistical analysis of microarrays, pathway 
enrichment analysis and immune cell type analysis 
using single sample gene set enrichment analysis. 
Immunohistochemistry was performed to validate specific 
results. The results were validated using 220 pretreatment 
samples from publicly available datasets at metalevel of 
pathway and survival analyses.
Results ΔTCD scores ranged from 12.4% to −47.7% 
and stratified patients into three response categories. At 
baseline, 40 genes were significantly upregulated in poor 
(n=12) versus good responders (n=21), including myeloid 
and stromal cell genes. Of several pathways showing 
significant enrichment at baseline in poor responders, 
epithelial to mesenchymal transition, coagulation, 
complement activation and apical junction pathways were 
validated in external cohorts. Unlike poor responders, 
good responders showed longitudinal (preradiotherapy vs 
postradiotherapy samples) upregulation of 198 immune 
genes, reflecting an increased T- cell- inflamed GEP, type- I 
interferon and macrophage populations. Longitudinal 
pathway analysis suggested viral- like pathogen responses 
occurred in post- treatment resected samples compared 
with pretreatment biopsies in good responders.
Conclusion This study suggests potentially druggable 
immune targets in poor responders at baseline and 
indicates that tumors with a good RT/CRT response 
reprogrammed from immune “cold” towards an 
immunologically “hot” phenotype on treatment with 
radiotherapy.
INTRODUCTION
More than 700 000 new cases and 300 000 
deaths of rectal cancer per annum were 
estimated in the Global Cancer Incidence, 
Mortality and Prevalence (GLOBOCAN) 
2018 report.1 These numbers are expected 
to rise, especially in young adults.1 2 Neoad-
juvant radiotherapy/chemoradiation (RT/
CRT) is a recommended strategy for the 
majority of patients presenting with locally 
advanced adenocarcinoma of the rectum.3 
Either short- course radiotherapy (25 Gy in 5 
fractions over 5 days) (SCRT) or long- course 
chemoradiation (45 Gy in 25 fractions over 
5 weeks concomitant with fluoropyrimidine- 
based chemotherapy) (LCRT) are estab-
lished regimens with similar (local) tumor 
control benefits.3
Only 20% of patients show a complete 
pathological response (pathCR) following 
RT/CRT and this is associated with signifi-
cantly better survival outcomes.3 4 In the 
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remaining 80%, a wide variation in response is observed. 
Some intensified neoadjuvant regimens, which include 
the addition of oxaliplatin, have shown improved rates 
of pathCR and organ preservation.5 6 However, a number 
of other regimens have failed to meet predefined clinical 
trial endpoints,4 driving the search for new therapeutic 
strategies.
At present, the standard for the assessment of rectal 
tumor response to neoadjuvant therapy is the tumor 
regression grade (TRG). A number of TRG systems exist, 
of which the American Joint Committee on Cancer (AJCC) 
TRG system has shown superior prediction of survival 
outcomes.7 However, the AJCC TRG has only four catego-
ries, meaning that considerable variation in radiotherapy 
response may occur within a single score. In addition, all 
TRG systems are limited by the subjectivity inherent to 
manual scoring and differences in interobserver agree-
ment.3 Evaluation of tumor cell density (TCD) involves 
point quantification of 300 individual tumor or stromal 
cells in H&E stained tumor sections.8 9 TCD is similar to 
TRG in that it assesses the relative proportion of tumor 
and stroma cells; however, in contrast to TRG, TCD does 
this using a linear and objective measurement. The use of 
TCD may therefore enable increased precision and detec-
tion of smaller differences in radiotherapy response than 
TRG.
The role of the tumor immune microenvironment in 
radioresponsiveness is increasingly recognized.10 However, 
a clear understanding of the immune biology underlying 
radioresponsiveness in rectal cancer is lacking. Microsat-
ellite instability occurs in less than 2% of rectal tumors,11 
and appears to be associated with greater responsiveness 
to chemoradiotherapy than neoadjuvant fluorouracil/
oxaliplatin, for reasons that are not fully understood.12 
Furthermore, aspects of tumor biology associated with 
response to novel immunomodulatory agents, such as 
tumor mutational burden and neoantigen load, do not 
show an association with radiotherapy response.11 13
Very few studies have reported immune gene expres-
sion changes associated with radioresponsiveness, or 
potential personalized radiotherapy approaches based 
on the underlying tumor immune microenvironment in 
rectal cancer.13 14 This is partly because of the paucity of 
rectal cancer- specific transcriptional datasets with paired 
preradiotherapy and postradiotherapy samples and well- 
annotated radiotherapy responses. Published reports 
that do exist have typically used a variety of different 
gene expression technologies and often evaluated non- 
overlapping gene sets. This has restricted their ability 
to validate novel findings in external cohorts and it has 
therefore been difficult to reach a consensus view on the 
gene signatures driving radiotherapy resistance in rectal 
cancer.
This study aimed to characterize the key immunological 
gene expression profiles (GEP), pathways and cell types 
associated with response or resistance to neoadjuvant 
RT/CRT at baseline and longitudinally (changes evolving 
during treatment). In the future, this characterization 
could inform the development of potential gene expres-
sion biomarkers (although not within the scope of the 
current manuscript) and novel immunotherapy combina-




Pretreatment biopsy and post- treatment resection spec-
imen archival blocks from patients who received SCRT 
or LCRT atNorth East – York Research Ethics Committee 
were retrieved (Research Ethics Committee No 08/
H0903/62). Clinicopathological characteristics of the 
patients were collected. Patients with a non- standard 
interval between the end of radiation and surgery (longer 
than 20 and 80 days for SCRT and LCRT, respectively) 
were excluded.
Definition of response to neoadjuvant therapy
All cases were reviewed and TRG was evaluated according 
to AJCC TNM Staging Manual (8th Edition)15 in resec-
tion specimens by a specialist gastrointestinal pathol-
ogist. In order to overcome the subjectivity inherent 
in the TRG system, a previously described quantitative 
method (TCD) was also evaluated.8 9 In brief, TCD evalu-
ation involves quantification of 300±15 individual points 
distributed across the whole tumor area on digital H&E- 
stained tumor sections (figure 1A, B). The selection of 
300 points is derived from earlier modeling studies which 
identified that at least 250 points were needed to accu-
rately quantify the percentage of tumor cells. Baseline 
and post- treatment TCD were assessed by an indepen-
dent observer, blinded to TRG evaluation.
Gene expression profiling
Following demarcation of tumors on H&E slides by a 
specialist gastrointestinal pathologist, tumor areas were 
macrodissected from unstained slides to capture the 
whole tumor microenvironment. Nucleic acids were 
extracted using The RecoverAll Total Nucleic Acid Isola-
tion Kit and quantified using Qubit Fluorometry (both 
from Thermo Fisher Scientific, UK), according to manu-
facturer’s instructions. The expression of 760 genes 
included in the NanoString panCancer Immune Panel 
(NanoString Technologies, Seattle, Washington) were 
measured according to manufacturer’s instructions and 
normalized using positive and negative controls and the 
housekeeping genes included in the panel. Only genes 
with non- zero expression in 75% or more of the samples 
were retained.16 The presence of a batch effect in log2 
transformed and normalized data was assessed using 
exploBatch17 and corrected using ComBat from SVA 
Bioconductor- based R package.18
TCD analysis
Patients’ characteristics were summarized using descrip-
tive statistics. The difference between resection specimen 
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and baseline TCD (ΔTCD) was calculated; its associa-
tion with TRG was assessed using the Kruskal- Wallis test. 
Next, ΔTCD was used to classify each patient’s tumor 
response into three categories (good, intermediate or 
poor) using k- means clustering. To determine GEP that 
were most relevant to differential radiotherapy responses, 
we excluded the intermediate response group and 
compared good versus poor responders in the majority of 
subsequent analyses (an H&E demonstration of good vs 
poor responders is shown in figure 2).
Immune gene expression, pathways and cell type analysis
The Estimation of STromal and Immune cells in MAlig-
nant Tumours using Expression data (ESTIMATE) algo-
rithm19 was used to infer tumor purity and the fraction of 
stromal and immune cells in baseline biopsies of tumors 
with good versus poor radiotherapy response. Following 
this, significance analysis of microarrays (SAM) was used 
to identify individual genes with a significant differ-
ence in expression at baseline between good and poor 
responders.20 A comparison of intermediate responders’ 
GEP with those of the good and poor responders was 
also performed. Following this, functional annotation 
of the significant genes according to pathways (hypeR R 
package21) and cell types was performed (using an Enrichr- 
based gene enrichment analysis22), and two publicly avail-
able gene sets (ARCHS4 and the Human Gene Atlas).23 24 
ARCHS4 is a published database of cell types derived by 
mining RNAseq data from public gene expression data-
bases.23 For Human Gene Atlas, the authors created 
custom microarrays to measure gene expression of known 
and predicted gene proteins associated with tissues and 
cell types.24 We used Enrichr combined score analysis to 
perform enrichment of cell types in our radiotherapy- 
treated rectal gene expression cohort.22 The pathways to 
genes plots were done using multiple packages—cluster-
Profiler,25 msigdbr26 and enrichplot.27
Longitudinal (treatment- induced) significant changes 
in gene expression were evaluated in paired samples of 
good and poor responders in two separate SAM analyses.20 
For pathway analysis, the Molecular Signature Database 
(MSigDB)’s hallmarks gene sets26 and hypeR R package21 
was used to describe the biological pathways represented 
Figure 1 Methodology for evaluation of tumor cell density (TCD) and allocation of radiotherapy response categories. (A) Virtual 
graticule of approximately 300 points applied to tumor area on a digital H&E section. (B) Demonstration of TCD point scoring. 
(C) Box and whisker plot to show the relationship between ΔTCD and American Joint Committee on Cancer (AJCC) Tumour 
Regression Grade System (TRG). (D, E) Allocation of three radiotherapy response groups according to change in TCD (ΔTCD) 
for short- course radiotherapy (SCRT) (D) and long- course chemoradiotherapy (LCRT) (E). The Kruskall- Wallis test was used for 
statistical comparisons.
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by differentially expressed genes. Similarly, longitudinal 
changes in the 18- gene T- cell- inflamed GEP,28 that is 
associated with prediction of immunotherapy response, 
were evaluated in good and poor responders. Of note, 
our panel included 16 of the 18 genes in the GEP. Finally, 
longitudinal immune cell type changes in good and poor 
responders were inferred using single- sample gene set 
enrichment analysis29 and immune enrichment signa-
tures (IES) from Rooney et al.30
Validation datasets and analysis
The use of different GEP platforms, non- overlapping 
genes and inconsistent measures of radiotherapy 
response across published reports poses challenges for 
independent validation of findings. To address this, meta- 
analysis at the level of gene sets/pathways was used to 
compare upregulated pathways according to response in 
our datasets with those in two independent cohorts.31 32 In 
addition, as our study cohort and the above two cohorts 
did not have survival outcomes available, the impact of 
differential gene expression on disease- specific survival 
(n=182) was assessed in a third independent and publicly 
available cohort—GSE87211 (n=188), where patients 
were treated with CRT.33
The first validation cohort consisted of GEP from 15 
patients receiving preoperative radiotherapy. Radio-
therapy response was defined using the Mandard tumor 
regression grade system where TRG1 and TRG2 were 
considered to be responders and TRG3, TRG4 and TRG5 
were classified as non- responders. PrimeView Affyme-
trix arrays were used for GEP using RNA extracted from 
microdissected epithelial and stromal components of 
fresh frozen preradiotherapy tumor tissue biopsies.31 We 
used the pathway analyses data, from a supplementary 
table of the Goncalves- Ribeiro study, derived from dysreg-
ulated genes in the stromal component of radiotherapy 
non- responders (compared with responders).31
The second validation cohort consisted of 23 patients 
with rectal cancer treated with preoperative radio-
therapy to a dose of 45 Gy in 25 fractions, 5 days per 
week for 5 weeks, ± 5.4 Gy boost. The AJCC TRG system 
was used to define radiotherapy response in surgical 
specimens; tumors were classified as “total responders” 
when assigned to TRG0, “partial responders” when 
TRG1 and TRG2, and “non- responders” when TRG3. 
Proteomics analysis was performed using high perfor-
mance liquid chromatography separation, coupled 
to mass spectrometry by the authors. We used the list 
of 139 proteins (from the supplementary table of the 
original publication) that discriminated non- responder 
from total responders to preoperative radiotherapy 
from Chauvin et al.32 We applied enrichment analysis 
using “Investigate Gene Sets” from the MSigDB26 to 
discern the changes in pathways associated with the 
“hallmarks gene sets”.
Figure 2 Example of H&E staining preradiotherapy and postradiotherapy in good versus poorly responding tumors defined 
using the change in tumor cell density (ΔTCD).
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The third validation cohort consisted of gene expres-
sion data (n=188) and disease- specific survival outcomes 
of 182 patients with locally advanced rectal cancer treated 
with preoperative radiotherapy to a dose of 50.4 Gy.33 GEP 
was carried out by the authors using the Human 4×44 K 
v2 array platform from Agilent Technologies (G4845A). 
Disease- specific survival measured from the time of 
surgery to death or last clinical follow- up was used.
To classify the samples from the third cohort into two 
classes that resemble poor and good responders from 
our cohort, average (mean) expression of 40 genes, 
significantly upregulated in poor responding samples 
from our cohort, was calculated for each sample. The 
optimal cutpoint for the mean expression was further 
calculated using the maximally selected rank statis-
tics from “survminer” R package using “surv_cutpoint” 
command. The optimal cutpoint provided two classes 
with high (representing poor- like responders) and low 
(representing good- like responders) expressors. These 
expressor groups arising from poor responding genes 
were further used to perform disease- specific survival and 
further gene expression analysis.
Immunohistochemistry
In order to provide further protein- level confirmation 
of the above gene expression findings, dual staining 
of CD68 and CD163 using immunohistochemistry was 
carried out in a limited number of samples due to the 
constraints of tissue availability. The immunohistochem-
istry methods for this are described in the online supple-
mental methods.
Statistics
Kruskal- Wallis, Fisher exact and t tests were applied where 
necessary. Survival analysis was carried out using Kaplan- 
Meier methods and the log rank test.
RESULTS
Study population and ΔTCD-based response to RT/CRT
A total of 140 archival blocks from 70 patients were identi-
fied (figure 3A). Eleven patients with a prolonged interval 
between the end of radiotherapy and surgery were 
excluded. Fifty- three cases with successful RNA extraction 
from diagnostic biopsies were available for analysis, of 
whom 52 cases had TRG scores. Patients’ characteristics 
are tabulated in figure 3B. In line with the published liter-
ature,3 4 the median age at diagnosis was 67 years and 72% 
of the patients were male. At least 45/53 (85%) of tumors 
were staged greater than pathological stage I after neoad-
juvant treatment.
TRG 2 (moderate response) was ascribed to 90.4% 
(47/52; leaving out one sample with TRG status unavail-
able) of the tumors; only 2 and 3 patients were scored as 
TRG 1 and 3, respectively, and no patients had a pathCR 
(TRG 0). Hence, the TRG, consistent with its known 
limitations,3 was not considered a suitable endpoint to 
identify differential response to neoadjuvant treatments. 
Conversely, the ΔTCD scores ranged from 12.3% to 
−47.7% and from 12.4% to −42.1% in patients treated 
with SCRT and LCRT, respectively.
Despite very few patients being categorized as TRG 
1 or 3, a marginal association between TRG and ΔTCD 
was seen (figure 1C). The three patients with TRG 3 had 
minimal ΔTCD (mean ΔTCD 0.96%) whereas the two 
patients with TRG 1 had much more substantial ΔTCD 
(mean ΔTCD −22.8%). As ΔTCD scoring better repre-
sented heterogeneous responses to neoadjuvant therapy, 
ΔTCD was subsequently used to define response catego-
ries. Following k- means clustering into three response 
groups, 23 good, 16 intermediate and 14 poor responders 
were identified (figure 1D, E). An example of H&E 
staining preradiotherapy and postradiotherapy in good 
versus poorly responding tumors is shown in figure 2. 
Here, the poorly responding postradiotherapy resection 
specimen shows a high density of residual tumor cells. 
Conversely, in the resection specimen showing a good 
response, there are very few tumor cells and the tissue is 
predominantly replaced by reactive stroma.
A comparison of clinicopathological characteristics 
in good versus poor responders indicated that poor 
responders were significantly younger with higher patho-
logical stage. Importantly, there was no significant differ-
ence between the two response categories and type of 
neoadjuvant treatment (SCRT or LCRT) or the interval 
between radiation and surgery (figure 3B). This rein-
forces the biological meaning of ΔTCD and suggests that 
significant associations with variation in radiotherapy 
technique are unlikely, at least in this cohort.
Immune profiles of baseline diagnostic biopsies in patients 
with ΔTCD good versus poor response to radiotherapy
Use of the ESTIMATE algorithm, which infers cancer 
versus stromal/immune content at the gene expression 
level, showed that, at baseline, poorly responding tumors 
contained a significantly higher fraction of stromal and 
immune cells (ie, lower tumor purity) than tumors with 
a good response (figure 4A–C). When the immune 
GEP at baseline of good and poor responders (n=33) 
were compared using SAM analysis, 40 genes showed 
significantly higher expression in poor compared with 
good responders (figure 4D). These included genes 
involved in immune checkpoint inhibition (CD274 or 
PD- L1), immune regulation (IL11, IL15RA, IL6R) and 
integrin signaling (ITGA1, ITGA4) as well as markers of 
macrophages (CD163, ITGAM) and stromal fibroblasts 
(PDGFR-β). Eight genes showed significantly (FDR≤0.05) 
differential expression when the three responder 
groups—good, intermediate and poor were compared by 
SAM analysis. Of these 8 genes, 7 genes overlapped with 
the 40 poor responder genes suggesting that the inter-
mediate responders were of an immune phenotype in 
between the good versus poor responders (online supple-
mental table 1).
Pathway analysis using the 40 upregulated genes in poorly 
responding tumors revealed 13 significantly (FDR<0.2) 
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upregulated hallmark pathways, where more than 50% of 
the pathways were associated with direct immune regula-
tion (figure 4E). The genes associated with four pathways 
showing the most significant upregulation in our cohort 
(IL6/JAK/STAT3 signaling, inflammatory response, 
interferon gamma response and allograft rejection) are 
shown as a pathways network with associated genes in 
figure 4F. More than 50% of these genes were shared by 
the four pathways representing similar mechanism(s) of 
antiviral- like immune regulation operating in the pretreated 
Figure 3 Consolidated Standards of Reporting Trials (CONSORT) diagram and clinical characteristics of samples. (A) 
CONSORT diagram to show patient samples’ flow through the study. (B) A table with baseline characteristics of patients with 
valid gene expression data. Good, intermediate and poor response categories are defined by ΔTCD. The Kruskall- Wallis test 
was used for statistical comparisons. AJCC, American Joint Committee on Cancer; LCRT, long- course chemoradiotherapy; 
SCRT, short- course radiotherapy; TRG, tumor regression grade; TCD, tumor cell density; NA, Not available; NS, not significant.
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poor responding samples compared with good responding 
samples.
We used two independent cohorts of rectal cancer 
samples for validation using pathway analysis derived 
using gene and protein expression, respectively. 
A third independent cohort with disease- specific 
survival was used for validation. Upregulation of the 
epithelial–mesenchymal transition, and apical junction 
pathways were validated in both independent cohorts 
and pathways of complement and coagulation were vali-
dated in one independent cohort (figure 4G–I, online 
supplemental table 2). These two cohorts served as inde-
pendent validation using both gene and protein expres-
sion profiles. The pathways from the first cohort were 
Figure 4 Analysis of baseline gene expression and pathways in preradiotherapy diagnostic biopsies. (A–C) Stromal score (A), 
immune score (B) and tumor purity (C) in baseline biopsies of tumors with good versus poor radiotherapy response using the 
Estimation of STromal and Immune cells in MAlignant Tumours using Expression data (ESTIMATE) algorithm.19 (D) Heat map 
of 40 genes showing significantly higher expression in the biopsies of poorly responding tumors versus tumors with a good 
response. (E) Pathway analysis of upregulated pathways in poor responders using Molecular Signature Database (MSigDB) 
Hallmarks. (F) Network showing upregulated pathways and corresponding genes in poorly responding tumors at baseline. 
(G–I) Pathway analysis in Leeds cohort (using hypergeometric test from hyper21 (G), validation cohort pathway analysis of gene 
signatures from Goncalves- Ribeiro et al (FDR values for pathways from the authors)31 (H) and validation cohort pathway analysis 
of protein signatures from Chauvin et al32 using GenePattern’s Investigate Gene Sets hypergeometric test26 (I). (J) Kaplan- Meier 
curves to show disease- specific survival outcomes of samples, from a publicly available gene expression (GSE87211) dataset 
treated with chemoradiotherapy, according to high or low expression of the 40 genes highly expressed in poor responding 
samples shown in (D). Expressors refer to samples with high or low expression of 40 genes from (D). The definition of the 
groups was described in methods sections. Since the 40 genes are highly expressed in poor responding samples in (D), high 
expressors were named as poor- like and low expressors as good- like samples from GSE87211 samples. The log- rank statistical 
test was applied for p value significance.
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generated from microdissected stroma. Hence, the genes 
enriched in the poor responding samples are potentially 
from stroma. In the third validation cohort, there was a 
trend towards inferior disease- specific survival outcomes 
in patients (high expressors or poor like) whose tumors 
had increased expression of the 40 genes upregulated in 
poor responders (from our training cohort) compared 
with those patients with tumors not showing increased 
expression (low expressors or good like; figure 4J). The 
mean expression of the 40 upregulated genes in poorly 
responding tumors in high versus low expressors and 
their expression patterns as a heatmap in the third vali-
dation cohort are shown in online supplemental figure 
1. These results show pathway- based and survival- based 
validation of the responder groups.
Functional annotation of the 40 genes using publicly 
available resources and enrichment analysis demon-
strated their significant association with macrophages, 
monocytes and dendritic cells, as well as stromal cells 
including fibroblasts and smooth muscle cells (figure 5A, 
B, online supplemental tables 3–6). CD163 is marker of 
alternatively- activated (M2- like) macrophages which are 
thought to have tumor- promoting effects.34 CD163 gene 
was significantly upregulated in poorly responding tumors 
(figure 5C). Dual staining of CD68 and CD163 using 
immunohistochemistry was possible for a very limited 
number of biopsies due to tissue availability. Neverthe-
less, figure 5D,E demonstrate marked upregulation of 
both CD68 and CD163 staining in the baseline biopsy of a 
poorly responding tumor when compared with the base-
line biopsy of the tumor showing a good radiotherapy 
response.
Radiation-induced immune changes in good and poor 
responders
Significant longitudinal changes in immune gene expres-
sion during radiotherapy were evaluated with two sepa-
rate SAM analyses in 15 paired samples (pretreatment 
biopsies and resection specimens) from patients with 
a good response and in 12 paired samples from poor 
responders. In good responders, 198 immune genes 
showed significant upregulation (figure 6A and online 
supplemental figure 2) in the postradiotherapy resec-
tion specimen when compared with the preradiotherapy 
biopsy. However, in poor responders, the expression of 
only seven genes was significantly modified by radio-
therapy treatment (C7, CHIT1, CXCL12, and SPP1 were 
upregulated and CCL28, DMBT1 and CEACAM1 were 
downregulated; figure 6B).
Significant increases in coinhibition of T- cells, type I 
interferon response and macrophages were demonstrated 
in good responders (figure 6C–E, the genes used in these 
signatures are show in figure 6F). Conversely, no signifi-
cant changes were observed in poor responders which, as 
described earlier, appeared to have a higher macrophage 
score at baseline (online supplemental figure 3A- C). 
Figure 5 Analysis of baseline cell populations in preradiotherapy diagnostic biopsies. (A, B) Enrichment analyses using 
ARCHS4 (A)23 and human gene atlas (B)24 tissue databases showing increased myeloid/monocyte cell populations and stroma 
in poorly responding tumors versus tumors with a good response. (C) Expression of CD163 gene in good (n=21) versus poor 
(n=12) responding tumors in baseline biopsies. (D, E) Immunohistochemistry for CD68 and CD163 protein in baseline biopsies 
of tumors showing poor (D) versus good (E) radiotherapy response, respectively.
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Similarly, a significant increase in the T- cell- inflamed 
GEP signature was demonstrated in good responders, 
but not in poorly responding tumors, which appeared 
to have a more inflamed GEP signature at baseline than 
good responders (figures 6G and 4D). Evaluation of IES 
showed a consistent, significant increase in the expression 
of 25 (out of 56) genes associated with multiple immune 
cell types (including CD8+ T cells and perforin; PRF1, 
and macrophages; Figure 6F) and processes in good 
responders. Conversely, such immune activation was not 
present in poor responders (except for two significant 
genes—PDCD11LG2 and CD70; figure 6F), which showed 
increased macrophage score at baseline (figure 5C).
To understand the biological pathways represented 
by the 198 upregulated genes in tumors with a good 
response, pathway analysis was performed. A highly 
significant upregulation of interferon gamma response, 
allograft rejection and inflammatory response pathways 
was seen alongside several other significantly (FDR<0.2) 
upregulated pathways (figure 7A). Taken together, these 
suggest an immunostimulatory response to radiotherapy, 
together with radiation- induced replacement of tumor 
cells with reactive stroma. Figure 7B shows the six most 
significantly upregulated pathways and their associated 
genes in a network with potential activation of antiviral 
pathways. The downstream effect of this activation is an 
interferon gamma response. We observed a highly signif-
icant increase in interferon- gamma response pathways 
scores in good responders (figure 7C).
DISCUSSION
In this study, immune GEP was conducted in 53 paired 
preradiotherapy and postradiotherapy rectal cancers 
Figure 6 Longitudinal analysis of changes in immune gene expression in matched preradiotherapy diagnostic biopsy 
and postradiotherapy resection specimen. (A, B) Significance analysis of microarrays (SAM) plot to show 198 genes with a 
significant difference in expression between pre- RT biopsy and post- RT resection in tumors with a good response (A) and those 
with a poor response (B). Four upregulated genes during RT in (B) include C7, CHIT1, CXCL12 and SPP1 while downregulated 
genes during RT include CCL28, DMBT1 and CEACAM1. Significant genes are shown in green while non- significant genes 
are shown in black. (C–E) Box plots showing changes in immune enrichments scores (IES)30 for T cell coinhibition (C), type 
I interferon (IFN) (D) and macrophages (E) between pre- RT biopsies and post- RT resection specimens in tumors showing a 
good RT response. (F) Heatmaps to show changes in significant IES in pre- RT biopsies and post- RT resection specimens in 
tumors showing a good RT response and a poor RT response. Certain genes were repeated depending on their immune cell 
type/regulation categories. A blue box highlights increased cytolytic activity and CD8+ T cells in post- RT resection samples 
compared with pre- RT biopsy samples. (G, H) Change in the T- cell- inflamed GEP28 between pre- RT biopsy and post- RT 
resection in good responders (G) and poor responders (H).
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to identify immune genes, pathways and cells associ-
ated with radiotherapy response. A unique quantitative 
method (ΔTCD) identified immune- related features 
of rectal cancers that showed a differential response to 
neoadjuvant RT/CRT. Although 47 of 52 tumors (90.4%) 
presented with the same TRG, ΔTCD allowed further 
refinement of response assessment with identification 
of three distinct groups and further comparison of good 
versus poor response groups. Of note, our study cohort 
did not include patients with a pathCR to radiotherapy.
The 40 immune genes and associated pathways signifi-
cantly upregulated in the baseline biopsies of tumors 
showing a poor response may potentially represent 
mechanisms of resistance to RT/CRT. These genes are 
a reflection of an inflamed yet immunosuppressive 
microenvironment enriched for specific myeloid popu-
lations and fibroblasts (stroma enriched). In addition, 
the upregulation of integrins suggests distinct interac-
tions between the extracellular matrix and cells within 
a fibrotic (PDGFR-β) and proangiogenic (VEGFC) tumor 
microenvironment. The corresponding upregulated 
biological pathways include epithelial–mesenchymal 
transition, apical junction signaling, allograft rejection 
and complement activation, three of these were validated 
in independent cohorts. Furthermore, the enrichment of 
the 40 genes in a separate cohort showed poor prognosis, 
demonstrating an adverse effect associated with the poor 
response to RT/CRT.
These data support further preclinical and clinical 
evaluation of agents, before and/or in combination with 
RT/CRT, which may modify these immunosuppressed 
and radio- resistant phenotypes and increase the chance 
of a good pathological response, which is associated 
with better long- term outcomes. We showed that poor 
radiotherapy responses were more common in younger 
patients; early onset sporadic rectal cancer appears to be 
increasing and there is a particular need for more biolog-
ical understanding and better therapeutic strategies in 
this context. A number of early phase clinical trials testing 
the feasibility and potential activity of immunotherapy or 
other drugs targeting the microenvironment in conjunc-
tion with RT/CRT are currently recruiting patients,35–38 
and our study supports the biological rationale of testing 
immune checkpoint inhibitors in particular in this 
setting. The heterogeneous immune phenotype at base-
line demonstrated in the current study may encourage 
and inform the use of biomarker- selected approaches in 
future.
In this study, baseline gene expression in small diag-
nostic biopsies was successfully measured using the 
nCounter platform (NanoString Technologies). This 
technology is approved for clinical use to help assess the 
risk of recurrence and potential benefit from adjuvant 
chemotherapy in breast cancer.39 Recently, our group vali-
dated customized small gene panels for subtype predic-
tion using a protocol modified for potentially affordable 
cost if applied in the clinic.16 40 Hence, these studies 
support the feasibility of using small customized gene 
expression signatures for prospective patient selection.
The longitudinal analyses have elucidated distinct 
differences in the radiation- induced immune response 
between good and poorly responding tumors which, to our 
knowledge, have not been described before. Tumors with 
a good response showed both increased T- cell inflamma-
tion and increased immune cytolytic activity, suggestive of 
a transition from immune “cold” to a more immunolog-
ically “hot” phenotype after RT/CRT. In this transition, 
the increase in the cytolytic marker perforin-1 (PRF1) at 
Figure 7 Pathway analysis of longitudinal gene expression changes during radiotherapy in tumors with a good response. 
(A) Pathway analysis of upregulated pathways during radiotherapy in good responders using Molecular Signature Database 
(MSigDB) and hallmarks gene sets. (B) Network mimicking viral (pathogen)- like response in resected tissues after radiotherapy. 
(C) Change in interferon- gamma response pathway score during radiotherapy in tumors showing a good response. IL, 
interleukin; IFN, interferon.
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the gene expression level is accompanied by a potential 
immunoregulatory response involving upregulation of 
immune checkpoints including CD274/PD- L1, LAG3, 
CTLA4, BTLA, TIGIT and others (figure 6F), as described 
previously.30 A timely identification of this immunoregu-
latory response after RT/CRT may provide a therapeutic 
opportunity to further enhance tumor response by the 
additional adjuvant use of immune checkpoint inhibitors.
In contrast, tumors with a poor response showed upreg-
ulation of IL6/JAK/STAT3, inflammatory and interferon 
pathways, among others, at baseline, with much less of a 
change in immune phenotype during neoadjuvant treat-
ment. These pathways closely overlap those upregulated 
following radiotherapy in good responders; however, the 
context in which this upregulation occurs is very different. 
At baseline, tumors with a poor response show intrinsic 
features of chronic inflammation and chronic interferon 
signaling, together with stromal fibroblast and myeloid 
cell enrichment. In both preclinical and clinical studies, 
such tumors are associated with immunosuppression and 
inferior outcomes following radiotherapy.41 42 Reciprocal 
oncogenic signaling between cancer and stromal cells 
and increased extracellular matrix may also contribute to 
poor therapy responses.43 44 In contrast, the longitudinal 
acute upregulation of inflammatory and interferon path-
ways in good responders is an acquired phenotype induced 
by therapy and associated with a reactive “wound repair” 
stroma.
Collectively, the above findings demonstrate the need 
to understand the baseline immune context of tumors 
alongside longitudinal treatment- induced immune 
changes, and highlights the complexity underlying the 
biology of tumor ‘inflammation’, with regard to baseline 
tumor intrinsic and treatment- induced characteristics, 
and their relevance to clinical outcome. For example, 
in poor responders, immune checkpoint inhibitors may 
be more powerful if used before/during RT/CRT as an 
“immune primer” to revert the baseline immunosuppres-
sive tumor phenotype with high levels of PD- L1 expres-
sion. In our study, SPP1 was one of the genes that was both 
upregulated in baseline biopsies of poor responders and 
showed a significant longitudinal increase in the same 
poor responders. A recent single cell sequencing anal-
ysis of immune and stromal populations in 18 colorectal 
tumors identified a proangiogenic, CAF- enriched, tumor- 
promoting SPP1+ tumor- associated macrophage popu-
lation (TAM).45 It is possible that our study identified 
SPP1 expression on tumor- promoting TAM which drive 
therapy resistance, in which case specific targeting of this 
population during rectal cancer radiotherapy is worthy of 
further study.
A longitudinal increase in the expression of genes 
associated with a type I interferon response was seen in 
tumors showing a good RT/CRT response. These data 
lend support to preclinical observations that the cGAS/
STING/type 1 interferon pathway, the biology of which 
is critical in the immune response to viral infection, is 
important in the radiation- induced immune response.46 47 
They also indicate that further study of the relationship 
between radiation- induced DNA damage and the immune 
response is warranted, including possible synergy with 
DNA damage response inhibitors13 48
Several other studies investigating the role of different 
immune cell markers have been reported in rectal 
cancer.13 14 49 50 In preradiotherapy biopsies, increased 
CD8+ T cells have been associated with a complete 
response to radiation,13 and high infiltration of both 
CD3+ and CD8+ cells with increased tumor downstaging 
after preoperative chemoradiotherapy.49 A study charac-
terizing CD8+ and FOXP3+ tumor- infiltrating lympho-
cytes in 237 biopsy and resection pairs showed that a 
significant decline in the intratumoral CD8+/FOXP3+ 
ratio after radiotherapy was associated with superior 
survival outcomes.50 However, this series looked at only 
CD8 and FOXP3 staining, and the relationship between 
these markers and more global gene expression reflecting 
the activation/suppression of all immune cell subtypes, 
remains unknown. Nevertheless, the above studies and 
our work collectively suggest that both tumor immune cell 
phenotyping and immune GEP may have roles in guiding 
personalized and/or combination radiation treatment.
This study has a number of limitations. First, our study 
cohort is fairly small, which means our findings are 
primarily hypothesis generating and precludes separate 
evaluation of LCRT and SCRT schedules. Nevertheless, 
there are not many studies in rectal cancer RT/CRT that 
have used a greater number of samples than our study. In 
order to further validate our findings, we have used two 
different cohorts (n=38) and pathway analysis derived 
from gene and protein expression, respectively. Second, 
long- term survival outcomes were also not available in our 
study cohort. However, in a third independent cohort 
(n=182), we have shown a trend towards inferior disease- 
specific survival in patients with the same upregulated 
genes as poor responding tumors in our study, despite the 
fact that disease- specific survival will be impacted by vari-
ation in surgical technique, systemic treatment following 
tumor recurrence and other factors that are unrelated to 
radiotherapy response. Furthermore, the TCD, used as an 
endpoint to define response, was previously significantly 
associated with recurrence- free survival in colorectal 
cancer, independently of age, pT- stage, pN- stage and 
extra- mural venous invasion.8 Additionally, in a recent 
phase II study of neo- adjuvant chemotherapy and radio-
therapy, TRG and TCD showed a highly significant asso-
ciation and, despite the small study size, a borderline 
significant relationship between TCD and progression- 
free survival was seen.51
We also acknowledge the possible presence of sampling 
errors associated with biopsies and, consequently their 
gene expression; validation of these results in more 
contemporary studies with TCD analysis, ideally with 
multiple biopsies taken from the same tumor to account 
for intratumoral heterogeneity, would be worthwhile. 
Finally, we acknowledge that the addition of immune 
checkpoint inhibition may lead to paradoxical T cell 
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exhaustion. Further study is needed to confirm the 
validity of specifically- timed radiotherapy/immuno-
therapy combinations suggested in this study, particularly 
in view of the lack of efficacy of immune checkpoint inhi-
bition in microsatellite stable colorectal cancer.
In summary, this study has used a unique quantitative 
evaluation (ΔTCD) to elucidate differences in RT/CRT 
response; ΔTCD has the potential to enhance treatment 
stratification in the clinic. Second, we have demonstrated 
the immunostimulatory role of RT/CRT in a subgroup of 
patients whose tumors have a baseline immunologically 
cold phenotype and continue to show a good response to 
RT/CRT. Third, we have performed pathway analysis to 
show potential viral mimicry phenotype hijacked by good 
responding tumors after radiotherapy to evade immune 
surveillance. Finally, this study suggests potential new 
therapeutic strategies using immunomodulatory agents 
and other targeted drugs in combination with RT/CRT 
to modify radiorefractory inflamed tumor phenotypes. 
Precisely timed administration of such agents in selected 
groups of patients may enable improved responses to 
neoadjuvant therapies in rectal cancer.
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